Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 2, 2010, Pages 286-302

  Moreira, Tailane Sant'Anna ^a   de Sousa, Valéria Pereira ^a   Pierre, Maria Bernadete Riemma ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULOSE ACETATE; LUMIRACOXIB; OLEIC ACID; POLOXAMER;

ARTICLE; ARTIFICIAL MEMBRANE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FLOW KINETICS; GELATION; IN VITRO STUDY; TEMPERATURE; VISCOSITY;

EID: 78650286865     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j34880     Document Type: Article

References (63)

1. Mysler E. Lumiracoxib (Prexige): a new selective cox-2 inhibitor. Int J Clin Pract 58: 606-611, 2004.
2. Tannenbaum H, Berenbaum F, Reginster J-Y, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Clin Rheumatol 25: 42-53, 2005.
3. Prescott SM. Is Cyclooxygenase-2 The Alpha and The Omega in Cancer. J Clin Invest 105: 1511-1513, 2000.
4. Ḿeric JM, Rottey S, Olaussen K, Soria J-C, Khayat D, Rixe O, Spano J-P. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59: 51-64, 2006.
5. Achiwa H, Yatabe Y, Hida T, Kuroishi T, Kozaki K, Nakamura S, Ogawa M, Sugiura T, Mitsudomi T, Takahashi T. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res, 5: 1001-1005, 1999.
6. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA.The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60: 5040-4, 2000.
7. Orengo F, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS. Celecoxib, a cyclooxygenase- 2 inhibitor as a potential chemopreventive to UVinduced skin cancer: a study in the hairless mouse model. Arch Dermatol 138: 751-5, 2002.
8. Afaq F, Adhami VM, Mukhtar H. Photochemoprevention of ultraviolet B signaling and Photocarcinogenesis Mutat Res 571: 153-173, 2005.
9. Acemoglu M, Allmendinger T, Calienni J, Cercus J, Loiseleur O, Gottfried H, Sedelmeier H, Xu D. Synthesis of new N-aryl oxindoles asintermediates for pharmacologically active compounds. Tetrahedron 60: 11571-11586, 2004.
10. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J Clin Pharmacol 64: 233-252, 2008.
11. Moreira TS, Sousa, VP, Pierre MBR. A Novel Transdermal Delivery System for the Anti-Inflammatory Lumiracoxib: Influence of Oleic Acid on In Vitro Percutaneous Absorption and In Vivo Potential Cutaneous Irritation. AAPS Pharm Sci Tech. 11 (2): 621-629, 2010.
12. Schmolka IR. Artificial skin. I. preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res 6: 571-582, 1972.
13. Johnston TP, Miller S. Toxicological evaluation of poloxamer vehicles for intramuscular uses, Parenter Drug Assoc 39: 83-88, 1985.
14. Moore H, Croy S, Mallapragada S, Pandit N. Experimental Investigation and Mathematical Modeling of Pluronic F127 Gel Dissolution: Drug release in Stirred Systems. J Control Rel 67: 191-202, 2000.
15. Edsman K, Carlfors J, Petersson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 6: 105-112, 1998.
16. Ma WD, Xu H, Wang C, Nie SF, Pan WS. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. Int J Pharm 350: 247-56, 2008.
17. ® F-127 gels containing unsaturated fatty acids Int J Pharm, 183: 125-132, 1999.
18. Koffi AA, Agnely F, Ponchel G, Grossiord JL. Modulation of the rheological and mucoadhesive properties of thermosensitive poloxamer-based hydrogels intended for the rectal administration of quinine. Eur J Pharm Sci 27: 328-335, 2006.
19. Miyazaki S, Tobiyama T, Takada M, Attwood D. Percutaneous absorption of indomethacin from pluronic F-127 gels in rats. J Pharm Pharmacol 47: 455-457, 1995.
20. Shin SC, Cho CW, Oh IJ. Enhanced efficacy by percutaneous absorption of piroxicam from the poloxamer gel in rats. Int J Pharm 17: 213-218, 2000.
21. Veyries ML, Couarraze G, Geiger S, Agnely F, Massias L, Kunzli B, Faurisson F, Rouveix B. Controlled release of vancomycin from Poloxamer 407 gels. Int J Pharm, 192: 183-193, 1999.
22. Paavola A. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm 199: 85-93, 2000.
23. Ricci EJ, Bentley MV, Farah M, Bretãs RE, Marchetti JM. Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci 17: 161-167, 2002.
24. Bentley MVLB, Marchetti JM, Ricardo N, Ali-Abi Z, Collett JH. Influence of lecithin on some physical chemical properties of poloxamer gels: rheological, microscopic and in vitro permeation studies. Int J Pharm 193: 49-55, 1999.
25. Escobar-Chávez JJ, López-Cervantes M, Naïk A, Kalia YN, Quintanar-Guerrero D, Ganem-Quintanar A. Applications of thermoreversible pluronic F-127 gels in pharmaceutical formulations, J Pharm Sci 9: 339-358, 2006.
26. Chi SCh, Do K, Tan HK, Chun HW. Antiinflammatory and analgesic transdermal gel, United States Patents., Patent number 5,527,832, 1996.
27. Shin SC, Cho CW, Oh IJ. Effects of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins. Int J Pharm 17: 199-203, 2001.
28. Escobar-Chavez JJ, Quintanar-Guerrero D, Ganem-Quintanar A. In vivo skin permeation of sodium naproxen formulated in pluronic F-127 gels: effect of Azone and Transcutol. Drug Dev. Ind. Pharm 31: 447-454, 2005.
29. Shawesh A, Kallioinen S, Hellen L, Antikainen O, Yliruusi J. Pluronic F-127 gels as a vehicle for topical formulations of indomethacin and rheological behavior of these formulations. Pharmazie 57: 186-90, 2002.
30. Yong CS, Choi J, Quan QZ, Rhee JD, Kim CK, Lim SJ, Kim KM, Oh PS, Choi HG. Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. Int J Pharm 226: 195-205, 2001.
31. Francoeur ML, Golden GM, Potts, RO. Oleic acid: its effects on stratum corneum in relation to (trans) dermal drug delivery. Pharm Res 7: 621-627, 1990.
32. Yamashita F, Koyama Y, Kitano M, Takakura Y, Hashida M. Analysis of in vivo skin penetration enhancement by oleic acid based on a two-layer diffusion model with polar and nonpolar routes in the stratum corneum. Int J Pharm 117: 173-179, 1995.
33. Larrucea E, Arellano A, Santoyo S, Ygartua P. Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin. Eur J Pharm Biopharm, 52: 113-9, 2001.
34. Pierre MBR, Ricci EJr, Tedesco AC, Bentley MVL. Oleic Acid as Optimizer of the Skin Delivery of 5-Aminolevulinic Acid in Photodynamic Therapy. Pharm Res 23: 360-366, 2006.
35. Lampe MA, Burlingame AL, Whitney JA, Willians ML, Brown BE, Roitman E, Elias, PM Human stratum corneum lipids: characterization and regional variations. J. Lipid Res 24: 120-130, 1983.
36. Escribano E, Calpena AC, Queralt J, Obach R, Doménech J. Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula. Eur J Pharm Sci 19 (4):203-210, 2003.
37. Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F. Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. PDA J Pharm Sci Technol 61 (4): 276-85, 2007.
38. Singh S, Gajra B, Rawat M, Muthu MS. Enhanced transdermal delivery of ketoprofen from bioadhesive gels. Pak J Pharm Sci 22 (2): 193-8, 2009.
39. Boelsma E, Tanojo H, Bodd HE and Ponec M. Assessment of the Potential Irritancy of Oleic Acid on Human Skin: Evaluation In Vitro and In Vivo. Toxicology in Vitro 10: 129-142, 1996.
40. Jiang J, Wang RK. Comparing the synergistic effects of oleic acid and dimethyl sulfoxide as vehicles for optical clearing of skin tissue in vitro. Phys Med Biol 49(23): 5283-94, 2004.
41. Vadnere M, Amidon G, Lindenbaum S, Haslam JL. Thermodynamic studies on the gel-sol transition of some pluronic polyols. Int J Pharm 22: 207-218, 1984.
42. Moreira TS, Cid YP, Kummerle AE, Fraga CAM, Pierre MBR, Sousa VP. Extração e purificação de fármacos anti-inflamatórios não esteroidais ciclooxigenase 2- seletivos. Quim Nova, 32 (5): 1324-1328, 2009.
43. Bonacucina G, Spina M, Misici-Falzi M, Cespi M, Pucciarelli S, Angeletti, M., Palmieri, G.F Effect of hydroxypropyl β-cyclodextrin on the selfassembling and thermogelation properties of Poloxamer 407. Eur J Pharm Sci, 32: 115-122, 2007.
44. Moreira TS, Pierre MBR, Fraga CAM, Sousa VP. Development and validation of HPLC and UV spectrophotometric methods for the determination of lumiracoxib in tablets. Journal of Basic and Applied Pharmaceutical Sciences 29 (3): 267-275, 2008.
45. Causon R. Validation of chromatographic methods in biomedical analysis viewpoint and discussion. J Chromatogr B 689: 175-180, 1997.
46. Proniuk S, Dixon SE, Blanchard J. Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms. J Pharm Dev Technol 6: 469-476, 2001.
47. Fugimoto RA, Mugrare B, Mcquire LW, Van Duzer JH. Certain 5-alkyl-2 arylaminophenylacetic acids and derivates, NOVARTIS-ERFINDUNGEN VERWALTUNGS-GESELLSHAFT MBH, Switzerland Patents, Patent number WO 99/11605, 1998.
48. Nair V, Panchagnula R. Poloxamer gel as vehicle for transdermal iontophoretic delivery of arginine vasopressin: evaluation of in vivo performance in rats. Pharmacol Res 47: 555-562, 2003.
49. Brummer R, Godersky S. Rheological studies to objectify sensations occurring when cosmetic emulsions are applied to the skin. Coll. Surf. A 152: 89-94, 1999.
50. Dumortier G, El Kateb N, Sahli M, Kedjar S, Boulliat A, Chaumeil JC. Development of a thermogelling ophthalmic formulation of cysteine. Drug Dev Ind Pharm 32 (1):63-72, 2006.
51. Miller SC, Drabik BR. Rheological properties of poloxamer neous absorption of piroxican from the poloxamer gel in rats. Int J Pharm 22: 207-218, 1984.
52. Gilbert JC, Richardson JL, Davies MC, Palin KJ, Hadgraft J. The effect of solutes and polymer on the gelation properties pluronic F-127 solution for controlled drug delivery. J Control Rel 5: 113-118, 1987.
53. Pisal SS, Paradkar AR, Mahadik KR, Kadam SS. Pluronic gels for nasal delivery of Vitamin B12. Part I, preformulation study. Int J Pharm 270: 37-45, 2004.
54. Choi H, Lee M, Kim M, Kim C. Effect of additives on the physicochemical properties of liquid suppository bases. Int J Pharm 190: 13-19, 1999.
55. Ryu JM, Chung SJ, Lee MH, Kim CK, Shim CK. Increased bioavailability of propranolol in rats by retaining thermally gelling liquid suppositories in the rectum. J Control Rel 59: 163-172, 1999.
56. Charrueau C, Tuleu C, Astre V, Grossiord JL, Chaumeil JC. Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids. Drug Dev Ind Pharm 27: 351-357, 2001.
57. Chang JY, Oh YK, Choi HG, Kim YB, Kim K. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int J Pharm 241: 155-163, 2002.
58. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Rel 85 (1-3):73-81, 2002.
59. Dumortier G, Grossiord JL, Agnely F, Chaummeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res 23: 2709-2728, 2006.
60. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 229: 29-36, 2001.
61. Takahashi A, Suzuki S, Kawasaki N, Kubo W, Miyazaki S, Loebenberg R, Bachynsky J, Attwood D. Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats. Int J Pharm 246: 179-186, 2002.
62. Schwartz JB, Simonelli AP, Higuchi WI. Drug release from wax matrices. Analysis of data with first-order kinetics and with the diffusioncontrolled model. J Pharm Sci 57: 274-277, 1968.
63. Lee HJ, Lee MH, Shim CK. Preparation and Evaluation of Ethyl Cellulose Microcapsules of Indomethacin. Arch Pharm Res 7: 33-40, 1984.